Latanoprost 0.005% and anterior segment uveitis

Acta Ophthalmol Scand. 1999 Dec;77(6):668-72. doi: 10.1034/j.1600-0420.1999.770612.x.


Purpose: To evaluate the association of latanoprost with anterior chamber uveitis in glaucoma patients.

Methods: We retrospectively reviewed 527 charts in latanoprost treated patients with: no prior uveitis (Group 1); prior uveitis but were inactive at the time of the study (Group 2); and active uveitis (Group 3).

Results: In Group 1 five (1.0%) of 505 patients developed uveitis after beginning latanoprost. The uveitis was trace to 1+ cell in severity and delayed in onset 99.8+/-73.9 days In Group 2 three of 13 (23.1%) patients developed delayed uveitis (trace to 1+ cell). In Group 3 zero of nine (0%) patients had worsened inflammation and the intraocular pressure remained unchanged (22.8+/-7.8 mmHg to 22.0+/-7.3 mmHg) after beginning latanoprost (p=0.38).

Conclusion: In patients without a prior history a mild delayed uveitis with latanoprost treatment may develop rarely. In patients with a uveitis history, a mild delayed exacerbation potentially may occur and the intraocular pressure may not be decreased in active uveitis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anterior Eye Segment / drug effects*
  • Anterior Eye Segment / pathology
  • Female
  • Glaucoma, Open-Angle / drug therapy
  • Humans
  • Incidence
  • Intraocular Pressure / drug effects*
  • Latanoprost
  • Male
  • Ocular Hypertension / drug therapy
  • Ophthalmic Solutions
  • Prostaglandins F, Synthetic / administration & dosage
  • Prostaglandins F, Synthetic / adverse effects*
  • Retrospective Studies
  • Texas / epidemiology
  • Uveitis, Anterior / chemically induced*
  • Uveitis, Anterior / epidemiology
  • Uveitis, Anterior / pathology


  • Ophthalmic Solutions
  • Prostaglandins F, Synthetic
  • Latanoprost